ADAURA三期试验更新分析:IB-IIIA期EGFR突变NSCLC术后辅助奥希替尼的三年安全性、耐受性及健康相关生活质量结局
ADAURA三期试验中,IB-IIIA期EGFR突变NSCLC完全切除术后患者1:1随机接受奥希替尼80mg或安慰剂每日一次最长3年。更新分析显示三年辅助奥希替尼未报告新安全信号,健康相关生活质量维持,支持其用于该人群。
要点
- 奥希替尼组中位总暴露35.8个月,安慰剂组25.1个月,多数不良事件在治疗起始12个月内首次报告。
- 奥希替尼组导致减量、中断、停药的不良事件分别为12%、27%、13%,安慰剂组分别为1%、13%、3%。
- 奥希替尼与安慰剂在SF-36躯体与心理成分总结恶化时间上无差异。
核心结论
- 三年辅助奥希替尼治疗未报告新的安全信号,健康相关生活质量得以维持。
- 结合显著的疗效获益,这些数据进一步支持奥希替尼用于IB-IIIA期EGFR突变NSCLC的辅助治疗。
研究设计与样本
- ADAURA为三期随机对照试验,患者1:1随机接受奥希替尼80mg或安慰剂每日一次,最长3年。
- 安全性分析集:奥希替尼组n=337,安慰剂组n=343;健康相关生活质量分析集:奥希替尼组n=339,安慰剂组n=343。
- 安全性评估在基线、第2周、第4周、第12周及此后每12周进行至治疗完成或终止,停药后28天评估。
- SF-36问卷在基线、第12周、第24周及此后每24周评估至复发、治疗完成或终止。
- 数据截止日期为2022年4月11日。
主要发现
- 中位(范围)总暴露时长奥希替尼组为35.8(0-38)个月,安慰剂组为25.1(0-39)个月。
- 多数不良事件在治疗起始12个月内首次报告:奥希替尼组97%,安慰剂组86%。
- 导致减量、中断或停药的不良事件在奥希替尼组分别为12%、27%、13%,在安慰剂组分别为1%、13%、3%。
- 导致奥希替尼减量或中断的最常见不良事件为口腔炎和腹泻;导致奥希替尼停药的最常见不良事件为间质性肺病(按方案)。
- 奥希替尼与安慰剂在SF-36躯体成分总结和心理成分总结的恶化时间上无差异。
临床怎么用
- 原文结论为三年辅助奥希替尼治疗未报告新的安全信号且健康相关生活质量维持,结合显著疗效获益,这些数据进一步支持奥希替尼用于IB-IIIA期EGFR突变NSCLC的辅助治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In ADAURA, adjuvant osimertinib significantly improved disease-free survival versus placebo in resected stage IB to IIIA EGFR-mutated NSCLC. We report in-depth analyses of three-year safety, tolerability, and health-related quality of life (HRQoL) from ADAURA. METHODS: Patients were randomized 1:1 to osimertinib 80 mg or placebo once daily for up to 3 years. Safety assessments were performed at baseline, week 2, week 4, week 12, and every 12 weeks until treatment completion or discontinuation, and 28 days after treatment was stopped. The SF-36 survey measured HRQoL at baseline, week 12, week 24, and every 24 weeks until recurrence, treatment completion or discontinuation. Data cutoff: April 11, 2022. RESULTS: Safety and HRQoL analysis sets: osimertinib, n = 337 and n = 339; placebo, n = 343 each. Median (range) total exposure duration was longer with osimertinib versus placebo: 35.8 (0-38) versus 25.1 (0-39) months. Most adverse events (AEs) were first reported within 12 months of starting treatment (osimertinib 97%, placebo 86%). AEs leading to dose reduction, interruption or discontinuation were reported in 12%, 27% and 13% respectively of patients with osimertinib; 1%, 13% and 3% with placebo. Stomatitis and diarrhea were the most common AEs leading to osimertinib dose reduction or interruption; interstitial lung disease was the most common leading to osimertinib discontinuation (per protocol). There were no differences in time to deterioration for SF-36 physical, mental component summaries between osimertinib and placebo. CONCLUSIONS: No new safety signals were reported and HRQoL was maintained with 3 years of adjuvant osimertinib treatment. Combined with significant efficacy benefit, these data further support adjuvant osimertinib in stage IB to IIIA EGFR-mutated NSCLC.
引用
- John T, Grohé C, Goldman JW, et al. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. J Thorac Oncol. 2023. PMID: 37236398. doi:10.1016/j.jtho.2023.05.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。